Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

American Journal of Hematology

Volumn 87, Issue 7, 2012, Pages 692-701

  Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; AZACITIDINE; BIOLOGICAL MARKER; LENALIDOMIDE; MICRORNA 29B; TET2 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW BIOPSY; CELL STRUCTURE; CHEMOTHERAPY; CHROMOSOME 5; CYTOGENETICS; CYTOPENIA; CYTOTOXICITY; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON CHELATION; KARYOTYPE; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; SCORING SYSTEM; SURVIVAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 84862554715     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23264     Document Type: Article

References (72)

1. Tefferi A, Vardiman JW.Myelodysplastic syndromes.N Engl J Med 2009; 361:1872-1885.
2. Garcia-Manero G, Fenaux P.Hypomethylating agents and other novel strategies in myelodysplastic syndromes.J Clin Oncol 2011;29:516-523.
3. Rollison DE, Howlader N, Smith MT, et al.Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.Blood 2008;112:45-52.
4. Goldberg SL, Chen E, Corral M, et al.Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.J Clin Oncol 2011;28:2847-2852.
5. Greenberg P, Cox C, LeBeau MM, et al.International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood 1997;89:2079-2088.
6. Dayyani F, Conley AP, Strom SS, et al.Cause of death in patients with lower-risk myelodysplastic syndrome.Cancer 2010;116:2174-2179.
7. Schanz J, Tuchler H, Sole F, et al.New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.J Clin Oncol [Research Support, Non-U.S. Gov't] 2012;30:820-829.
8. Tong WG, Quintas-Cardama A, Kadia T, et al.Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system.Cancer 2012 [Epub ahead of print].
9. Vardiman JW, Thiele J, Arber DA, et al.The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: Rationale and important changes.Blood 2009;114:937-951.
10. Haase D, Germing U, Schanz J, et al.New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients.Blood 2007;110:4385-4395.
11. Naqvi K, Jabbour E, Bueso-Ramos C, et al.Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.Blood. [Evaluation Studies]. 2011;118:4690-4693.
12. Young NS, Calado RT, Scheinberg P.Current concepts in the pathophysiology and treatment of aplastic anemia.Blood 2006;108:2509-2519.
13. Malcovati L, Germing U, Kuendgen A, et al.Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.J Clin Oncol 2007;25:3503-3510.
14. Malcovati L, Porta MG, Pascutto C, et al.Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making.J Clin Oncol 2005;23:7594-7603.
15. Malcovati L, Della Porta MG, Strupp C, et al.Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).Haematologica. [Research Support, Non-U.S. Gov't] 2011;96:1433-1440.
16. Kantarjian H, O'Brien S, Ravandi F, et al.Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.Cancer 2008;113:1351-1361.
17. Garcia-Manero G, Shan J, Faderl S, et al.A prognostic score for patients with lower risk myelodysplastic syndrome.Leukemia 2008;22:538-543.
18. Bejar R, Stevenson K, Caughey B, et al.Validation of a prognostic model and the impact of SF3B1, DNMT3A, and other mutations in 289 genetically characterized lower risk MDS patient samples.Blood 2011:abstract969.
19. Naqvi K, Garcia-Manero G, Sardesai S, et al.Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model.J Clin Oncol. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't. Research Support, U.S. Gov't, P.H.S.].2011;29:2240-2246.
20. Della Porta MG, Malcovati L, Strupp C, et al.Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.Haematologica. [Research Support, Non-U.S. Gov't] 2011;96:441-449.
21. Bejar R, Levine R, Ebert BL.Unraveling the molecular pathophysiology of myelodysplastic syndromes.J Clin Oncol 2011;29:504-515.
22. Bejar R, Stevenson K, Abdel-Wahab O, et al.Clinical effect of point mutations in myelodysplastic syndromes.N Engl J Med 2011;364:2496-2506.
23. Itzykson R, Kosmider O, Cluzeau T, et al.Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.Leukemia 2011:1147-1152.
24. Papaemmanuil E, Cazzola M, Boultwood J, et al.Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.N Engl J Med [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.].2011;365:1384-1395.
25. Makishima H, Visconte V, Sakaguchi H, et al.Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.Blood 2012;119:3203-3210.
26. Sekeres MA, Schoonen WM, Kantarjian H, et al.Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys.J Natl Cancer Inst [Research Support, N.I.H., Extramural] 2008;100:1542-1551.
27. Moyo V, Lefebvre P, Duh MS, et al.Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: A meta-analysis.Ann Hematol 2008;87:527-536.
28. Jadersten M, Malcovati L, Dybedal I, et al.Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.J Clin Oncol 2008;26:3607-3613.
29. Jadersten M, Montgomery SM, Dybedal I, et al.Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.Blood. 2005;106:803-811.
30. Park S, Grabar S, Kelaidi C, et al.Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience.Blood 2008;111:574-582.
31. List A, Dewald G, Bennett J, et al.Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.N Engl J Med 2006;355:1456-1465.
32. List A, Kurtin S, Roe DJ, et al.Efficacy of lenalidomide in myelodysplastic syndromes.N Engl J Med 2005;352:549-557.
33. Raza A, Reeves JA, Feldman EJ, et al.Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.Blood 2008;111:86-93.
34. Fenaux P, Giagounidis A, Selleslag D, et al.A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.Blood. [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2011;118:3765-3776.
35. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study.Lancet Oncol 2009;10:223-232.
36. Kantarjian H, Issa JP, Rosenfeld CS, et al.Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study.Cancer 2006;106:1794-1803.
37. Lyons RM, Cosgriff TM, Modi SS, et al.Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.J Clin Oncol 2009;27:1850-1856.
38. Garcia-Manero G, Gore SD, Cogle C, et al.Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.J Clin Oncol 2011;29:2521-2527.
39. Garcia-Manero G, Couriel D, Tambaro F, et al.A phase II randomized Bayesian study of very low dose subcutaneous decitabine administered daily or weekly times three in patients with lower risk myelodysplastic syndrome (MDS).Blood 2009;114:119.
40. Olnes MJ, Sloand EM.Targeting immune dysregulation in myelodysplastic syndromes.JAMA 2011;305:814-819.
41. Saunthararajah Y, Nakamura R, Wesley R, et al.A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.Blood 2003;102:3025-3027.
42. Sloand EM, Olnes MJ, Shenoy A, et al.Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.J Clin Oncol 2011;28: 5166-5173.
43. Zou JX, Rollison DE, Boulware D, et al.Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.Leukemia 2009;23:1288-1296.
44. Garg R, Faderl S, Garcia-Manero G, et al.Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.Leukemia 2009;23:1297-1302.
45. Lim ZY, Killick S, Germing U, et al.Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin.Leukemia 2007;21:1436-1441.
46. Passweg JR, Giagounidis AA, Simcock M, et al.Immunosuppressive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99.J Clin Oncol 2011;29:303-309.
47. Cutler CS, Lee SJ, Greenberg P, et al.A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome.Blood 2004;104:579-585.
48. Koreth J, Pidala J, Perez W, et al.A decision analysis of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for older patients with de-novo myelodysplastic syndrome (MDS): Early transplantation offers survival benefit in higher-risk MDS.Blood 2011:abstract115.
49. Takatoku M, Uchiyama T, Okamoto S, et al.Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.Eur J Haematol 2007;78:487-494.
50. Sanz G, Nomdedeu B, Such E, et al.Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome.Blood 2008;112:640.
51. Greenberg PL, Attar E, Bennett JM, et al.Myelodysplastic syndromes.J Natl Compr Canc Netw 2011;9:30-56.
52. Kantarjian H, Oki Y, Garcia-Manero G, et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.Blood 2007;109:52-57.
53. Steensma DP, Baer MR, Slack JL, et al.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: The alternative dosing for outpatient treatment (ADOPT) trial.J Clin Oncol 2009;27:3842-3848.
54. Lubbert M, Suciu S, Baila L, et al.Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.J Clin Oncol [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2011;29:1987-1996.
55. Blum W, Garzon R, Klisovic RB, et al.Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.Proc Natl Acad Sci USA 2010;107:7473-7478.
56. Silverman LR, Demakos EP, Peterson BL, et al.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B.J Clin Oncol 2002;20:2429-2440.
57. Kornblith AB, Herndon JEII, Silverman LR, et al.Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study.J Clin Oncol 2002;20:2441-2452.
58. Garcia-Manero G, Gore SD.Future directions for the use of hypomethylating agents.Semin Hematol 2005;42(Suppl 2):S50-S59.
59. Sekeres MA, List AF, Cuthbertson D, et al.Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.J Clin Oncol [Clinical Trial, Phase I Multicenter Study Research Support, N.I.H., Extramural]. 2010;28:2253-2258.
60. Itzykson R, Kosmider O, Cluzeau T, et al.Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS.Blood 2010:abstract439.
61. Ko M, Huang Y, Jankowska AM, et al.Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.Nature 2010;468:839-843.
62. Yang H, Fang Z, Wei Y, et al.Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.Am J Hematol 2011;86:237-238.
63. Itzykson R, Thepot S, Quesnel B, et al.Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.Blood 2011;117:403-411.
64. Wattel E, De Botton S, Luc Lai J, et al.Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: Incidence of long-term survivors and outcome of partial responders.Br J Haematol 1997;98:983-991.
65. Beran M, Shen Y, Kantarjian H, et al.High-dose chemotherapy in high-risk myelodysplastic syndrome: Covariate-adjusted comparison of five regimens.Cancer 2001;92:1999-2015.
66. Chang C, Storer BE, Scott BL, et al.Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.Blood 2007;110:1379-1387.
67. Van Gelder M, Schetelig J, Volin L, et al.Monosomal karyotype predicts poor outcome for MDS/sAML patients with chromosome 7 abnormalities after allogeneic stem cell transplantation for MDS/sAML. A study of the MDS subcommittee of the chronic leukemia working party of the European group for blood and marrow transplantation (EBMT).Blood 2009;114:293.
68. de Lima M, Giralt S, Thall PF, et al.Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study.Cancer 2010;116:5420-5431.
69. Jabbour E, Garcia-Manero G, Batty N, et al.Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.Cancer 2010;116: 3830-3834.
70. Oussenko IA, Holland JF, Reddy EP, Ohnuma T.Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.Cancer research. [Research Support, Non-U.S. Gov't]. 2011;71:4968-4976.
71. Malcovati L, Papaemmanuil E, Bowen DT, et al.Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Blood 2011;118:6239-6246.
72. Thol F, Kade S, Schlarmann C, et al.Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.Blood 2012;119:3578-3584.